Content of botulinum neurotoxin in botox®vistabel ®, dysport®azzalure®, and xeomin®bocouture

Drugs in R and D

Volumn 10, Issue 2, 2010, Pages 67-73

  Frevert, Jrgen ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Botulinum toxin A; general; Neurotoxin

Indexed keywords

AZZALURE; BOCOUTURE; BOTULINUM TOXIN A; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM BOTULINUM; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BOTULINUM TOXINS, TYPE A; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUINEA PIGS; NEUROMUSCULAR AGENTS; NEUROTOXINS; RABBITS;

EID: 79953221849     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11584780-000000000-00000     Document Type: Article

References (27)

1. Jankovic J, Albanese A, Attassi MZ, et al. Botulinum toxintherapeutic clinical practice and science. Philadelphia (PA): Saunders Elsevier, 2009
2. Bhidayasiri R, Truong DD. Evidence for effectiveness of botulinum toxin for hyperhidrosis. J Neural Transm 2008;115(4):641-5 (Pubitemid 351534035)
3. Smith CP. Botulinum toxin in the treatment of OAB, BPH, and IC. Toxicon 2009 Oct; 54(5):639-46
4. Fagien S, Carruthers JD. A comprehensive review of patientreported satisfaction with botulinum toxin type A for aesthetic procedures. Plast Reconstr Surg 2008 Dec; 122(6):1915-25
5. Rossetto O, Morbiato L, Caccin P, et al. Presynaptic enzymatic neurotoxins. J Neurochem 2006 Jun; 97(6):1534-45 (Pubitemid 43873651)
6. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992 Mar; 56(1):80-99
7. Lietzow MA, Gielow ET, Le D, et al. Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J 2008 Dec; 27 (7-8): 420-5
8. Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 1992 Jan; 239(1):16-20
9. Panjwani N, O'Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J 2008;1(1):153-66
10. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005 Jun. 14; 64(11):1949-51 (Pubitemid 40800714)
11. Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006 Mar; 113(3):303-12 (Pubitemid 43201097)
12. Sattler G. Comparison of the efficacy and safety of NT 201, free of complexing proteins, with a licensed botulinum toxin type A in the treatment of glabellar frown lines. IMCAS conference; 2010 Jan 8-11; Paris
13. ® [abstract]. Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders. Mov Disord 2008;23(S1): S20-1
14. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007;67(5):669-83 (Pubitemid 46535642)
15. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005 Aug; 20(8):937-44 (Pubitemid 41419507)
16. Allergan Inc. BOTOX (Botulinum toxin type A) purified neurotoxin complex: prescribing information revised March 2010 [online]. Available from URL: http://www.allergan.com/assets/pdf/botox-pi.pdf [Accessed 2010 Jul. 26]
17. Speywood Pharmaceuticals Limited. Dysport Clostridium botulinum type A toxin-haemagglutinin complex: prescribing information revised 1994. Speywood Pharmaceuticals Limited: Maidenhead (now Ipsen, Slough, UK), 1994
18. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. BiotechnolAnnu Rev 2008;14:191-202 (Pubitemid 351903454)
19. Ekong TA, McLellan K, Sesardic D. Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations. J Immunol Methods 1995 27; 180(2):181-91
20. Das Gupta BR, Sathyamoorthy V. Purification and amino acid composition of type A botulinum neurotoxin. Toxicon 1984;22(3):415-24 (Pubitemid 14050791)
21. International Conference on Harmonization Guideline Q2B validation of analytical procedures: methodology. US FDA, 1997
22. ® is stable without refrigeration: complexing proteins are not required for stability of botulinum neurotoxin type A preparations [abstract and poster]. Toxins conference; 2008 Jun. 12-14, Baveno. Toxicon 2008;51 Suppl. 1:13
23. Hunt TJ. Improved botulinum toxin composition. US Patent application 2007/0025019 [online]. Available from URL: http://www.wipo.int/pctdb/en/wo.jsp? wo=2007016018&IA=US2006028603&DISPLAY=DESC. [Accessed 2010 Jul. 23]
24. Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins (chapter 32). In: Jankovic J, Albanese A, Attassi MZ, et al., editors. Botulinum toxin-therapeutic clinical practice and science. Philadelphia (PA): Saunders Elsevier, 2009
25. Goodnough MC, Johnson EA. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol 1992 Oct; 58(10):3426-8
26. Shone CC, Tranter HS. Growth of clostridia and preparation of their neurotoxins. Curr Top Microbiol Immunol 1995;195:143-60
27. Data on file. Merz Pharmaceuticals GmbH, 2004